Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 91Stomach Neoplasms 44Pancreatic Neoplasms 37Rectal Neoplasms 29Colonic Neoplasms 23Neoplasms 22Esophageal Neoplasms 21Squamous Cell Carcinoma of Head and Neck 20Neoplasm Metastasis 18Cholangiocarcinoma 16Adenocarcinoma Of Esophagus 16Biliary Tract Neoplasms 13Parkinson Disease 4, Autosomal Dominant Lewy Body 12Head and Neck Neoplasms 12Esophageal Squamous Cell Carcinoma 12Carcinoma, Non-Small-Cell Lung 12Adenocarcinoma 12Urinary Bladder Neoplasms 11Ovarian Neoplasms 9Gastrointestinal Neoplasms 9Carcinoma, Hepatocellular 7Endometrial Neoplasms 6Breast Neoplasms 6Gallbladder Neoplasms 5Advanced Solid Tumors 5Uterine Cervical Neoplasms 4Peritoneal Neoplasms 4Lung Neoplasms 4Carcinoma 4Appendiceal Neoplasms 4

Interventions

irinotecan sucrosofate 1Oxaliplatin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Small Intestine Cancer × Fluorouracil × 1 year × Clear all
NCT07060014 2025-07-11

NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers

The Methodist Hospital Research Institute

Phase 1 Not yet recruiting
22 enrolled
Gastrointestinal

Advanced Small Intestine Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡